The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has ...

Sandoz (OTCQX:SDZXF), which was spun out of Swiss pharma giant Novartis (NVS) (OTCPK:NVSEF) in 2023, has developed an FDA-approved biosimilar version of Enbrel called Erelzi, and its lawsuit comes ...

Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...

Amgen, Inc. AMGN announced the launch of its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States. The Enbrel Mini single-dose prefilled cartridges, used with the ...

By last year, those Enbrel sales had shrunk to $690 million. In the lawsuit, Sandoz said that within a year of Erelzi’s launch in Europe, the price of Enbrel had declined by 50% and biosimilars ...

In 2024, Enbrel generated $3.3 billion in revenue in the US. Sandoz received US FDA approval for Erelzi in 2016, the same year the company launched the medicine in Europe.

Enbrel’s sticker price, before rebates, has risen more than 1,500% since 1998, she said. “We look forward to the board’s continued efforts to meaningfully address the harms that the high ...

Here’s the backstory: Enbrel was the centerpiece of a 2002 deal in which Amgen acquired another company called Immunex that had developed the medicine. Later, Amgen reworked old patent ...

Last week, Colorado’s board declared that Enbrel, which costs more than $46,000 per year per patient, per the state’s claims database, is unaffordable for Colorado patients.

Amgen profit tops expectations on Enbrel sales, tax credit By Reuters January 27, 20151:12 PM PSTUpdated January 27, 2015 ...